National statistics data show that Denmark’s GDP experienced a surge of 1.7% year-on-year during the first half of this year. However, a closer look reveals a crucial contributor to this growth – the pharmaceutical industry, without which the nation’s economy would have contracted by 0.3%.
Novo Nordisk, Denmark’s pharmaceutical powerhouse and — as of September — Europe’s largest entity by market capitalization, has played a pivotal role in this economic transformation. The company’s success can be attributed to the skyrocketing demand for anti-obesity drugs, driven by two flagship products: the widely popular anti-diabetic medication Ozempic, and the anti-obesity drug Wegovy.
Jonas Petersen, an analyst at Statistics Denmark, expressed his astonishment, stating, “We’ve never seen anything like it; it changes the appearance of the economy.” Novo Nordisk’s performance has not only bolstered government revenues but has also had a positive impact on employment rates and shareholder profits.
It changed the appearance of the economy so much that the country had to publish GDP data that did not include Novo Nordisk.
An X user points out that a similar phenomenon occurred in Ireland in 1998 when the sales of the impotence drug Viagra boosted the country’s GDP to “unbelievable” levels.
Novo Nordisk saw a 157% increase in sales of anti-obesity treatments during the first half of this year. These results have prompted Novo Nordisk to revise its forecasts, with sales expected to surge by 30% in 2023, following its 2022 sales of 176.95 billion kroner (US$16.51 billion).
RELATED: Not Just Inflation: People Are Buying Less Food, Joe Weisenthal Suggests Ozempic May Be to Blame
The company’s market capitalization has now surpassed 2,984 billion kroner (over US$421 billion), exceeding Denmark’s GDP, which stood at 2,832 billion kroner (US$398.3 billion) last year.
As mentioned earlier, on September 1st, the company surpassed the market capitalization of LVMH, a global luxury goods giant, making it the largest listed company in Europe, a position held by the French conglomerate for over two and a half years.
Information for this story was found via the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
